Faulty node repair and dynamically spawned black hole search

New threats to networks are constantly arising. This justifies protecting network assets and mitigating the risk associated with attacks. In a distributed environment, researchers aim, in particular, at eliminating faulty network entities. More specifically, much research has been conducted on locating a single static black hole, which is defined as a network site whose existence is known a priori and that disposes of any incoming data without leaving any trace of this occurrence. However, the prevalence of faulty nodes requires an algorithm able to (a) identify faulty nodes that can be repaired without human intervention and (b) locate black holes, which are taken to be faulty nodes whose repair does require human intervention. In this paper, we consider a specific attack model that involves multiple faulty nodes that can be repaired by mobile software agents, as well as a virus v that can infect a previously repaired faulty node and turn it into a black hole. We refer to the task of repairing multiple faulty nodes and pointing out the location of the black hole as the Faulty Node Repair and Dynamically Spawned Black Hole Search. Wefirst analyze the attack model we put forth. We then explain (a) how to identify whether a node is either (1) a normal node or (2) a repairable faulty node or (3) the black hole that has been infected by virus v during the search/repair process and, (b) how to perform the correct relevant actions. These two steps constitute a complex task, which, we explain, significantly differs from the traditional Black Hole Search. We continue by proposing an algorithm to solve this problem in an

WMAP constraints on inflationary models with global defects

We use the cosmic microwave background angular power spectra to place upper limits on the degree to which global defects may have aided cosmic structure formation. We explore this under the inflationary paradigm, but with the addition of textures resulting from the breaking of a global O(4) symmetry during the early stages of the Universe. As a measure of their contribution, we use the fraction of the temperature power spectrum that is attributed to the defects at a multipole of 10. However, we find a parameter degeneracy enabling a fit to the first-year WMAP data to be made even with a significant defect fraction. This degeneracy involves the baryon fraction and the Hubble constant, plus the normalization and tilt of the primordial power spectrum. Hence, constraints on these cosmological parameters are weakened. Combining the WMAP data with a constraint on the physical baryon fraction from big bang nucleosynthesis calculations and high-redshift deuterium abundance, limits the extent of the degeneracy and gives an upper bound on the defect fraction of 0.13 (95% confidence).Comment: 10pp LaTeX/RevTeX, 6 eps figs; matches accepted versio

Unified dark energy models : a phenomenological approach

A phenomenological approach is proposed to the problem of universe accelerated expansion and of the dark energy nature. A general class of models is introduced whose energy density depends on the redshift $z$ in such a way that a smooth transition among the three main phases of the universe evolution (radiation era, matter domination, asymptotical de Sitter state) is naturally achieved. We use the estimated age of the universe, the Hubble diagram of Type Ia Supernovae and the angular size - redshift relation for compact and ultracompact radio structures to test whether the model is in agreement with astrophysical observation and to constrain its main parameters. Although phenomenologically motivated, the model may be straightforwardly interpreted as a two fluids scenario in which the quintessence is generated by a suitably chosen scalar field potential. On the other hand, the same model may also be read in the context of unified dark energy models or in the framework of modified Friedmann equation theories.Comment: 12 pages, 10 figures, accepted for publication on Physical Review

Is cosmology consistent?

We perform a detailed analysis of the latest CMB measurements (including BOOMERaNG, DASI, Maxima and CBI), both alone and jointly with other cosmological data sets involving, e.g., galaxy clustering and the Lyman Alpha Forest. We first address the question of whether the CMB data are internally consistent once calibration and beam uncertainties are taken into account, performing a series of statistical tests. With a few minor caveats, our answer is yes, and we compress all data into a single set of 24 bandpowers with associated covariance matrix and window functions. We then compute joint constraints on the 11 parameters of the ``standard'' adiabatic inflationary cosmological model. Out best fit model passes a series of physical consistency checks and agrees with essentially all currently available cosmological data. In addition to sharp constraints on the cosmic matter budget in good agreement with those of the BOOMERaNG, DASI and Maxima teams, we obtain a heaviest neutrino mass range 0.04-4.2 eV and the sharpest constraints to date on gravity waves which (together with preference for a slight red-tilt) favors ``small-field'' inflation models.Comment: Replaced to match accepted PRD version. 14 pages, 12 figs. Tiny changes due to smaller DASI & Maxima calibration errors. Expanded neutrino and tensor discussion, added refs, typos fixed. Combined CMB data, window and covariance matrix at http://www.hep.upenn.edu/~max/consistent.html or from [email protected]

Identification of 181Hg and shape coexistence in odd-A Hg isotopes

In-beam γ-ray transitions in 181Hg, the lightest odd-A Hg isotope known thus far, have been identified from fragment mass-γ and γ-γ coincidence measurements. Five prolate deformed rotational bands were placed in the level scheme. A decoupled band built on the strongly prolate deformed 1/2-[521] ground state was observed up to 29/2-. A 5/2-[512] configuration is suggested for a pair of strongly coupled bands displaying no signature splitting. The other two bands are also signature partner bands. They are populated with the largest intensity and exhibit splitting. They have been associated with the mixed neutron i13/2 orbitals and are proposed to decay to an i13/2 isomeric state associated with an oblate state

Search for supersymmetry at √S=8TeV in final states with jets and two same-sign leptons or three leptons with the ATLAS detector

A search for strongly produced supersymmetric particles is conducted using signatures involving multiple energetic jets and either two isolated leptons (e or μ) with the same electric charge, or at least three isolated leptons. The search also utilises jets originating from b-quarks, missing transverse momentum and other observables to extend its sensitivity. The analysis uses a data sample corresponding to a total integrated luminosity of 20.3 fb−1 of √s = 8 TeV proton-proton collisions recorded with the ATLAS detector at the Large Hadron Collider in 2012. No deviation from the Standard Model expectation is observed. New or significantly improved exclusion limits are set on a wide variety of supersymmetric models in which the lightest squark can be of the first, second or third generations, and in which R-parity can be conserved or violated

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Production of Υ(nS) mesons in Pb+Pb and pp collisions at 5.02 TeV

A measurement of the production of vector bottomonium states, Υ ( 1S ) , Υ ( 2S ) , and Υ ( 3S ) , in Pb + Pb and p p collisions at a center-of-mass energy per nucleon pair of 5.02 TeV is presented. The data correspond to integrated luminosities of 1.38 nb − 1 of Pb + Pb data collected in 2018, 0.44 nb − 1 of Pb + Pb data collected in 2015, and 0.26 fb − 1 of p p data collected in 2017 by the ATLAS detector at the Large Hadron Collider. The measurements are performed in the dimuon decay channel for transverse momentum p μ μ T < 30 GeV , absolute rapidity | y μ μ | < 1.5 , and Pb + Pb event centrality 0–80%. The production rates of the three bottomonium states in Pb + Pb collisions are compared with those in p p collisions to extract the nuclear modification factors as functions of event centrality, p μ μ T , and | y μ μ | . In addition, the suppression of the excited states relative to the ground state is studied. The results are compared with theoretical model calculations

Location-based anonymization: comparison and evaluation of the Voronoi-based aggregation system

Hospitals and health care organizations collect large amounts of detailed health care data that is in high demand by researchers. Thus, the possessors of such data are in need of methods that allow for this data to be released without compromising the confidentiality of the individuals to whom it pertains. As the geographic aspect of this data is becoming increasingly relevant for research being conducted, it is important for an anonymization process to pay due attention to the geographic attributes of such data. In this paper, a novel system for health care data anonymization is presented. At the core of the system is the aggregation of an initial regionalization guided by the use of a Voronoi diagram. We conduct a comparison with another location-based system of anonymization, GeoLeader. We show that our system is capable of producing results of a comparable quality with a much faster running time